Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on July 27, 2022, to announce its financial results for the second quarter of 2022. The report primarily references a press release issued on July 28, 2022, which contains the detailed financial outcomes for the quarter. Investors should refer to this press release for specifics on revenue, earnings, and any forward-looking guidance provided by the company.
Key Highlights
- 1Company announced its Q2 2022 financial results via press release.
- 2The 8-K filing incorporates the press release by reference.
- 3Investors should consult the furnished press release (Exhibit 99.1) for detailed financial performance and operational updates.
- 4The filing serves as a notification of the financial results release.
- 5No new financial statements or material agreements are included directly in the 8-K, only a reference to the press release.
Frequently Asked Questions
The main purpose of this 8-K filing is to formally report that Edwards Lifesciences has issued a press release containing its financial results for the second quarter of 2022. It serves as a notification to the SEC and the public.
The detailed financial results are located in the press release dated July 28, 2022, which is furnished as Exhibit 99.1 and incorporated by reference into this 8-K filing.
No, this specific 8-K filing does not contain new financial statements or material contracts directly. It solely references the press release where the Q2 2022 financial results are presented.